← All organizations
Highest phase reached
Phase 3
First clinical trial
Jun 1, 2004First marketed drug
Jun 27, 2018First NDA
Jun 27, 2018Last known activity
Nov 13, 2020
Acquired by Pfizer on Jun 17, 2019
Timeline
1990s
- Jan 1, 1998
Array BioPharma— Founded
2010s
- Jun 27, 2018
binimetinib— NDA Organization
- Jun 27, 2018
binimetinib— NDA Secondary Org
- Jun 17, 2019
Pfizer— Acquired By
Drugs by trial phase (69 distinct, 92 trials)
Phase 3 (9 own, 0 via acquisition)
Phase 2 (34 own, 0 via acquisition)
Phase 1 (26 own, 0 via acquisition)
Indications
Approved for
Studied for
- Adenocarcinoma
- Arthritis
- Arthritis, Rheumatoid
- Asthma
- Astrocytoma
- Brain Neoplasms
- Breast Neoplasms
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Cardiomegaly
- Cardiomyopathies
- Cardiomyopathy, Dilated
- Cardiomyopathy, Hypertrophic
- Colonic Neoplasms
- Colorectal Neoplasms
- Diabetes Mellitus, Type 2
- Disease Progression
- Fallopian Tube Neoplasms
- Gastrointestinal Stromal Tumors
- Glioblastoma
- Gliosarcoma
- Hypertrophy
- Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Plasma Cell
- Liver Diseases
- Lung Neoplasms
- Lymphoma
- Melanoma
- Multiple Myeloma
- Myelodysplastic Syndromes
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Neoplasms, Second Primary
- Neurofibroma
- Neurofibroma, Plexiform
- Neurofibromatoses
- Neurofibromatosis 1
- Noonan Syndrome
- Osteoarthritis
- Osteoarthritis, Knee
- Pancreatic Neoplasms
- Preleukemia
- Rectal Neoplasms
- Spondylitis
- Spondylitis, Ankylosing
- Syndrome
- Toothache
- Triple Negative Breast Neoplasms
- Uveal Neoplasms
Marketed drugs (2)
Recent trials (50)
- NCT04598009CollaboratorPhase 2Nov 13, 2020
- NCT04375527CollaboratorPhase 2Jun 1, 2020
- NCT04292119CollaboratorPhase 1/Phase 2Mar 31, 2020
- NCT04074967CollaboratorPhase 1/Phase 2Oct 30, 2019
- NCT04044430CollaboratorPhase 1/Phase 2Sep 1, 2019
- NCT03878719Lead sponsorPhase 1Jul 31, 2019
- NCT04005144CollaboratorPhase 1Jul 1, 2019
- NCT03971409CollaboratorPhase 2Jul 1, 2019
- NCT03911869Study directorPhase 2Jun 13, 2019
- NCT03911869Lead sponsorPhase 2Jun 13, 2019
- NCT03915951Study directorPhase 2Jun 4, 2019
- NCT03915951Lead sponsorPhase 2Jun 4, 2019
- NCT03843775CollaboratorPhase 1/Phase 2Feb 14, 2019
- NCT03693170CollaboratorPhase 2Oct 31, 2018
- NCT03637491CollaboratorPhase 2Aug 15, 2018
Details
- Founded
- Boulder, CO, US Jan 1, 1998
- First NDA
- Jun 27, 2018
- Last known activity
- Nov 13, 2020
Designations held
- Orphan drug